Grifols, S.A. (NASDAQ:GRFS) Given Average Recommendation of “Hold” by Analysts

Grifols, S.A. (NASDAQ:GRFS) has been given an average rating of “Hold” by the five brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $10.00.

Several research analysts have issued reports on the stock. JPMorgan Chase & Co. dropped their target price on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. Wall Street Zen raised shares of Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a report on Thursday, January 22nd. Finally, Zacks Research downgraded Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, December 5th.

Institutional Trading of Grifols

A number of institutional investors have recently made changes to their positions in GRFS. Allworth Financial LP grew its position in Grifols by 15.7% during the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 1,096 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Grifols by 17.2% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,459 shares of the biotechnology company’s stock worth $512,000 after purchasing an additional 8,121 shares during the period. Oppenheimer Asset Management Inc. grew its stake in shares of Grifols by 10.2% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 69,732 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 6,447 shares during the period. R Squared Ltd increased its holdings in shares of Grifols by 12.4% during the 4th quarter. R Squared Ltd now owns 23,455 shares of the biotechnology company’s stock valued at $219,000 after purchasing an additional 2,595 shares in the last quarter. Finally, NBC Securities Inc. lifted its stake in shares of Grifols by 10.4% in the 4th quarter. NBC Securities Inc. now owns 62,945 shares of the biotechnology company’s stock valued at $589,000 after purchasing an additional 5,911 shares during the period.

Grifols Trading Down 3.7%

Grifols stock opened at $9.19 on Friday. Grifols has a fifty-two week low of $6.19 and a fifty-two week high of $11.14. The company has a 50 day moving average price of $9.09 and a 200-day moving average price of $9.48. The company has a quick ratio of 0.93, a current ratio of 2.48 and a debt-to-equity ratio of 1.20.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.